Check Claims Before You Publish

 Quick Explanation Copied

 Long Explanation

Evidence From Key Papers

Plebani's flagship consensus work defines the IFCC Model of Quality Indicators — 57 QIs spanning pre-analytical (35), intra-analytical (7), and post-analytical (15) phases plus 3 support processes — establishing an international benchmarking platform (www.ifcc-mqi.com). Limitations include voluntary participation, self-reported data, and incomplete cross-national standardization MQI consensus model.

His analytical validation work is empirically solid: an LC-MS/MS method for sirolimus/everolimus achieved 3.5-min runs, intra-day CVs of 2.4–4.7%, inter-day CVs of 4.3–6.6%, and UK-NEQAS external biases of −2.0% (sirolimus) and −1.1% (everolimus) — though ascomycin (non-isotope-labelled) internal standard and single-SRM transitions are acknowledged weaknesses LC-MS/MS immunosuppressant validation.

Clinical diagnostic studies are adequately powered but demographically narrow: the KLK3/f-tPSA prostate cancer study (n=1,058; 401 cancers) found f/tPSA superior to total PSA, yet relied on single-biopsy gold standards KLK3/f-tPSA diagnostic study. COVID-era biomarker work (presepsin, n=75, AUC 0.72 for mortality) is provocative but small and single-center Presepsin COVID prognostic cohort. The antibody-waning study honestly reports ~90% 6-month decline and assay standardization problems, but the small selected HCW cohort limits generalizability Comirnaty antibody kinetics.

Citation Metrics

OpenAlex attributes ~1,962 works, ~64,785 citations, and h-index 110 to the primary Mario Plebani profile — elite within laboratory medicine. The provided Semantic Scholar subset (h=24, 1,518 citations, 92 papers) captures only a fragment, illustrating well-known cross-database fragmentation; note also the near-namesake confusion risk with frequent co-author Giuseppe Lippi (h=124).

Blindspots

Several studies show small samples (n=32 colorectal PIIIP cohort PIIIP recurrence study; n=75 presepsin), industry funding in a linagliptin cross-over trial (sponsor: Boehringer-Ingelheim) Linagliptin BNP cross-over trial, and consensus/policy papers lacking empirical validation Test evaluation framework. Overall: methodologically careful, quality-focused, high-impact — more systematizer than disruptive innovator. Confidence: moderate; review restricted to 10 supplied papers plus author metadata.

 BGPT Author Review

Scientific Quality

Strong cumulative metrics and quality-leadership, tempered by incremental novelty and occasional industry funding.

Communication Quality

Writing is professional and limitation-transparent; educational outreach (CME programs) shows communication investment.

Author Novelty

Systematizing contributions (MQI, test-evaluation frameworks) are novel within the field; empirical papers largely confirm or extend known biomarkers.

Scientific Rigor

Explicit limitations, external QA, and careful statistics throughout; small samples and industry funding are the main detractors.